Paricalcitol-D6 - CAS# 2070009-67-3 T Kinase Inhibitor InChi: InChI=1S/C25H16O9/c1-12(26)31-15-4-7-19-21(10-15)33-22-11-16(32-13(2)27)5-8-20(22)25(19)18-6-3-14(23(28)29)9-17(18)24(30)34-25/h3-11H

InChi: InChI=1S/C25H16O9/c1-12(26)31-15-4-7-19-21(10-15)33-22-11-16(32-13(2)27)5-8-20(22)25(19)18-6-3-14(23(28)29)9-17(18)24(30)34-25/h3-11H

Ziprazidone is approved for the treatment of schizophrenia

GSK-429286A

for the treatment of cancer

Need ultrasonic) H2O : 13

Paricalcitol-D6 - CAS# 2070009-67-3 T Kinase Inhibitor InChi: InChI=1S/C25H16O9/c1-12(26)31-15-4-7-19-21(10-15)33-22-11-16(32-13(2)27)5-8-20(22)25(19)18-6-3-14(23(28)29)9-17(18)24(30)34-25/h3-11HParicalcitol D6 is the deuterated form of Paricalcitol(Zemplar), which is a drug used for the prevention and treatment of secondary hyperparathyroidism (excessive secretion of parathyroid hormone) associated with chronic renal failure. IC50 value: Target: Vd analogChemically, it is 19 nor 1,25 (OH)2 vitamin D2 or 19 nor 1,25 dihydroxyvitamin D2, being an analog of 1,25 dihydroxyergocalciferol, the active form of vitamin D2. Product information CAS